Financial Contrast: Impax Laboratories (IPXL) vs. Innocoll (INNL)

Impax Laboratories (NASDAQ: IPXL) and Innocoll (NASDAQ:INNL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Earnings & Valuation

This table compares Impax Laboratories and Innocoll’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Impax Laboratories $824.43 million 1.72 -$472.03 million ($6.25) -3.06
Innocoll N/A N/A N/A ($1.66) -1.42

Innocoll has lower revenue, but higher earnings than Impax Laboratories. Impax Laboratories is trading at a lower price-to-earnings ratio than Innocoll, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Impax Laboratories and Innocoll’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Impax Laboratories -56.59% 9.06% 2.87%
Innocoll -1,051.20% N/A -138.53%

Insider & Institutional Ownership

91.5% of Impax Laboratories shares are owned by institutional investors. Comparatively, 34.2% of Innocoll shares are owned by institutional investors. 3.2% of Impax Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Impax Laboratories and Innocoll, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Impax Laboratories 0 9 5 0 2.36
Innocoll 0 2 1 0 2.33

Impax Laboratories presently has a consensus price target of $20.29, suggesting a potential upside of 6.21%. Innocoll has a consensus price target of $3.00, suggesting a potential upside of 27.66%. Given Innocoll’s higher probable upside, analysts plainly believe Innocoll is more favorable than Impax Laboratories.

Summary

Impax Laboratories beats Innocoll on 8 of the 11 factors compared between the two stocks.

Impax Laboratories Company Profile

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Innocoll Company Profile

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.

Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply